Breastfeeding after breast cancer is safe

Share :
Published: 14 Sep 2024
Views: 131
Rating:
Save
Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

Dr Eva Blondeaux speaks to ecancer about an international cohort study which looked into breastfeeding after breast cancer in young BRCA carriers.

She explains that pregnancy after breast cancer diagnosis and treatment is safe for patients carrying germline BRCA pathogenic or likely pathogenic variant, however there is no data on the feasibility and safety of breastfeeding in BRCA carriers.

Dr Blondeaux reports that this study shows that breastfeeding is feasible and safe with no difference in locoregional recurrence or second primary breast cancer events.

Breastfeeding after breast cancer is safe

Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

We previously demonstrated that pregnancy after breast cancer is safe for the mother, with no increased risk of recurrences even among BRCA carriers, but to date there are very few data regarding breastfeeding after breast cancer, also in BRCA carriers. We aim to provide the first evidence on this topic, on the feasibility and safety of breastfeeding, because we know that from the ipsilateral breast the surgery and radiotherapy can impact the women’s ability to breastfeed. Thus, there were concerns among oncologists on how to counsel these patients regarding safety and feasibility, because no data were available on maternal safety and on recurrences in these patients.

Our aim was to evaluate feasibility and safety. We included almost 5,000 young BRCA carriers with a history of breast cancer at a young age, and among those more than 600 had a pregnancy after breast cancer, of whom 474 had a live birth, so were able to decide whether to breastfeed or not. Among those 474 patients, almost half had a risk-reducing mastectomy before delivery, so were not even able to breastfeed. Among these women, around one out of five opted for breastfeeding. We firstly demonstrated that breastfeeding is safe, with no increased risk of recurrences in these women, and we also observed that women that decided to breastfeed were more frequently nulliparous at the time of breast cancer diagnosis, and did not report prior smoking habit. So maybe lifestyle factors can influence the women’s decision to breastfeed.

What is the impact of this study?

Our findings will hopefully improve the way we counsel these patients, because until today no data were available; this is the first evidence specifically focusing on BRCA carriers. So we really hope that our results will improve the knowledge and help clinicians to counsel these patients, because in BRCA carriers there is a consistent risk of relapse and risk of a second primary breast cancer in this population. Thus, patients are frequently counselled regarding the possibility of undergoing risk-reducing mastectomy. But still, if the patient is willing to breastfeed, we firstly demonstrate that is safe, so we can reassure these patients that they will not have increased risk of second primary breast cancers and local regional recurrences.

Related Videos

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg
Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )
10 Jul 2025

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC

Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC ( Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK )
1 Nov 2024

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
14 Sep 2024

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
13 Jun 2024

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )
12 Jun 2024

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )
3 Jun 2024

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
2 Jun 2024

The advancements in radiotherapy for breast cancer patients

Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia
The advancements in radiotherapy for breast cancer patients ( Prof Ahlam Dohal - King Fahd Specialised Hospital Dammam, Dammam, Saudi Arabia )
1 Feb 2023

Cancer pain management

Prof Ebtesam Ahmed - St John's University New York, New York City, USA
Cancer pain management ( Prof Ebtesam Ahmed - St John's University New York, New York City, USA )
1 Feb 2023